GLTO Galecto

Galecto to Participate at Upcoming Investor Conferences

Galecto to Participate at Upcoming Investor Conferences

BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that management will present and be available for one-on-one meetings at the following upcoming conferences:

  
BofA Securities 2022 Healthcare Conference
Date: Tuesday, May 10
Time:3:40 pm ET / 12:40 pm PT
Presentation:
  
A replay of the presentation will be available on the investors portion of the company’s website.
  
H.C. Wainwright Global Investment Conference
Date: May 23-26
Time:On demand presentation
Register:
  

About Galecto

Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 (and the galectin family generally) and LOXL2. Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an oral LOXL2 inhibitor (GB2064) in a phase 2 trial for the treatment of myelofibrosis; (iii) an oral galectin-3 inhibitor (GB1211) in a phase 1b/2a trial in liver cirrhosis and (iv) an oral galectin-3 inhibitor (GB1211) in a planned phase 2 trial for the treatment of NSCLC in combination with atezolizumab (Tecentriq®).

Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit .

For more information, contact:

Galecto, Inc. 
Hans Schambye, CEO

 
Jon Freve, CFO 
 
  
Investors/USMedia/EU
Ashley R. Robinson

Sandya von der Weid

+1 617 430 7577



EN
02/05/2022

Underlying

GLTOGalecto

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galecto

 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Closing of Public Offering and Full Exercise of the ...

Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its previously announced underwritten public offering of 16,644,737 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 2,171,052 additional s...

February 12, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Pricing of $275 Million Underwritten Public Offering

Galecto Announces Pricing of $275 Million Underwritten Public Offering BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a public offering price of $19.00 per share. In addition, Galecto has granted the underwriters a 30-day option to purchase an a...

February 11, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Proposed Underwritten Public Offering of Common Stoc...

Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, Series C non-voting convertible preferred stock. All of the securities are being offered by Galecto. In addition, Galecto i...

February 10, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Highlights Key Strategic Priorities and Anticipated 2026 Miles...

Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administrationRecent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical OfficerPipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026Cash balance...

January 12, 2026 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Announces Key Additions to Leadership Team

Galecto Announces Key Additions to Leadership Team Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for IND submission in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Cash balance, including $285 million raised in November 2025 PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinica...

January 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch